View Older Stories View More Recent Stories

May 26, 2021 06:32AM Emergent BioSolutions (EBS) Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
May 26, 2021 06:30AM Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
May 26, 2021 06:30AM Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
May 6, 2021 06:30AM Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
May 6, 2021 06:30AM Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
May 5, 2021 04:05PM Emergent BioSolutions to Participate in Investor Conferences
May 5, 2021 04:05PM Emergent BioSolutions to Participate in Investor Conferences
Apr 30, 2021 09:28AM Pre-Open Stock Movers 04/30: (LAUR) (WDC) (TEAM) Higher; (MVIS) (ARDX) (TWTR) Lower (more...)
Apr 29, 2021 05:31PM After-Hours Stock Movers 04/29: (TEAM) (LAUR) (AMZN) Higher; (MVIS) (ARDX) (CRUS) Lower (more...)
Apr 29, 2021 04:05PM Emergent BioSolutions Reports Financial Results for First Quarter 2021
Apr 29, 2021 04:05PM Emergent BioSolutions Reports Financial Results for First Quarter 2021
Apr 21, 2021 12:50PM Emergent BioSolutions (EBS) committed to working with the FDA and Johnson & Johnson to quickly resolve issues
Apr 21, 2021 12:46PM Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
Apr 21, 2021 12:46PM Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
Apr 15, 2021 06:30AM Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
Apr 15, 2021 06:30AM Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
Apr 5, 2021 06:15AM Emergent BioSolutions (EBS) On Track with Respect to COVID-19 Commitments; Receives Modified Task Order from U.S. to Support Opportunity for Further Expansion of Manufacturing Capacity for J&J (JNJ)
Apr 4, 2021 10:09PM Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further
Apr 4, 2021 10:09PM Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Fur
Apr 2, 2021 08:00AM Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
Apr 2, 2021 08:00AM Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
Mar 1, 2021 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Mar 1, 2021 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Feb 18, 2021 04:05PM Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 18, 2021 04:05PM Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 4, 2021 06:30AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
Feb 4, 2021 06:30AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
Jan 25, 2021 08:30AM Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Jan 10, 2021 02:00PM Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
Jan 10, 2021 02:00PM Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
Jan 4, 2021 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Jan 4, 2021 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Dec 29, 2020 04:05PM Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
Dec 29, 2020 04:05PM Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
Nov 5, 2020 04:05PM Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
Nov 5, 2020 04:05PM Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
Oct 15, 2020 06:30AM Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
Oct 15, 2020 06:30AM Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
Oct 8, 2020 04:07PM Emergent BioSolutions (EBS) Begins Phase 3 Clinical Trial to Evaluate Plasma-Derived Therapy COVID-HIG to Treat COVID-19
Oct 8, 2020 04:05PM Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
Oct 8, 2020 04:05PM Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
Aug 26, 2020 06:34AM Emergent BioSolutions (EBS) Names Marvin White to Board
Aug 26, 2020 06:30AM Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
Aug 26, 2020 06:30AM Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
Aug 18, 2020 06:31AM Emergent BioSolutions to Participate in Virtual Investor Conferences
Aug 18, 2020 06:31AM Emergent BioSolutions to Participate in Virtual Investor Conferences
Jul 30, 2020 04:27PM Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
Jul 30, 2020 04:27PM Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
Jul 27, 2020 06:33AM Emergent BioSolutions (EBS) Reports Agreement to AstraZeneca (AZN) to Expand Manufacturing for COVID-19 Vaccine Candidate
Jul 27, 2020 06:30AM Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
View More Recent Stories View Older Stories